MedTrace Logo

NanoFUSE® PL Gutter PMCF

NCT03751943 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-11-23

No results posted yet for this study

Summary

This study is a Post Market Follow Up Study to compare the fusion rates between the NanoFUSE® Bioactive Matrix (75%) w/autograft (25%) and autogenous bone in posterolateral gutter spinal fusion.

Conditions

  • Degenerative Disc Disease

Interventions

DEVICE

NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)

NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter

Sponsors & Collaborators

  • NanoFUSE Biologics, LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-31
Primary Completion
2021-03-31
Completion
2021-03-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03751943 on ClinicalTrials.gov